Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11126 - 11150 of 11533 in total
Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).
Investigational
Matched Description: … Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides …
GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced vomiting; functional dyspepsia; depression and anxiety.
Investigational
Matched Description: … GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced …
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Matched Description: … ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment …
Styphnolobium japonicum flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Styphnolobium japonicum flower bud is a plant/plant extract used in some OTC (over-the-counter) products …
Camellia japonica seed oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Camellia japonica seed oil is a plant/plant extract used in some OTC (over-the-counter) products. …
Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects).
Investigational
Matched Description: … Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability …
SLV-334 is under investigation in clinical trial NCT00735085 (A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.).
Investigational
Matched Description: … SLV-334 is under investigation in clinical trial NCT00735085 (A Phase 2a Dose Escalation Study With SLV334 …
Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).
Investigational
Matched Description: … Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on …
JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies).
Investigational
Matched Description: … JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination …
Darigabat is under investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder).
Investigational
Matched Description: … Darigabat is under investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, …
Investigational
Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study,...
Investigational
Matched Description: … In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent ... and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of …
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid ... Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a
Dirlotapide is a drug employed in the treatment of obesity in dogs. It is marketed by Pfizer and Zoetis under the brand name, Slentrol, and is not intended for human use.
Investigational
Vet approved
Matched Description: … Dirlotapide is a drug employed in the treatment of obesity in dogs. …
S-777469 is under investigation in clinical trial NCT00703573 (A Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis).
Investigational
Matched Description: … S-777469 is under investigation in clinical trial NCT00703573 (A Randomized, Double-blind Study to Evaluate …
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
Matched Description: … SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector …
Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects).
Investigational
Matched Description: … Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the …
Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.
Investigational
Matched Description: … Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that …
CA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. It is converted by cellular esterases to CA-074.[A258234,A258239]
Experimental
Matched Description: … CA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. …
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body mass in male rats and stimulates sexual behavior in female rats.
Experimental
Matched Description: … A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body …
An element with atomic symbol Cd, atomic number 48, and atomic weight 112.41. It is a metal and ingestion will lead to CADMIUM POISONING.
Experimental
Matched Description: … It is a metal and ingestion will lead to CADMIUM POISONING. …
Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)).
Investigational
Matched Description: … Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy …
TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
Investigational
Matched Description: … TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability …
Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Investigational
Matched Description: … Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, …
Displaying drugs 11126 - 11150 of 11533 in total